Grifols (GRFS) Cash & Equivalents Growth (1y) (2010 - 2025)
Grifols (GRFS) Cash & Equivalents Growth (1y) (2010 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash & Equiv. Growth (1y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
70.76% |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
-43.63% |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
81.47% |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
44.55% |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
-38.27% |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
36.64% |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
-3.76% |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
19.09% |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
- |
| 10 |
Grifols |
- |
- |
- |
-11.85% |
| Date | Value |
|---|
| Dec 31, 2025 |
-11.85% |
| Dec 31, 2024 |
83.99% |
| Dec 31, 2023 |
1.62% |
| Dec 31, 2022 |
-81.70% |
| Dec 31, 2021 |
342.97% |
| Dec 31, 2020 |
-15.85% |
| Sep 30, 2020 |
36.92% |
| Mar 31, 2020 |
7.39% |
| Dec 31, 2019 |
-30.40% |
| Sep 30, 2019 |
30.21% |
| Mar 31, 2019 |
-36.97% |
| Dec 31, 2018 |
13.04% |
| Jun 30, 2018 |
-3.28% |
| Dec 31, 2017 |
8.02% |
| Jun 30, 2017 |
-9.53% |
| Dec 31, 2016 |
-22.83% |
| Sep 30, 2016 |
1.32% |
| Jun 30, 2016 |
-99.90% |
| Mar 31, 2016 |
23.30% |
| Dec 31, 2015 |
-7.15% |
